- Home
- FEBO vs TXMD Comparison
FEBO vs TXMD Comparison
Compare FEBO & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- TXMD
- Stock Information
- Founded
- FEBO 1993
- TXMD 2008
- Country
- FEBO Hong Kong
- TXMD United States
- Employees
- FEBO N/A
- TXMD N/A
- Industry
- FEBO
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- TXMD Health Care
- Exchange
- FEBO Nasdaq
- TXMD Nasdaq
- Market Cap
- FEBO 12.6M
- TXMD 13.5M
- IPO Year
- FEBO 2023
- TXMD N/A
- Fundamental
- Price
- FEBO $0.99
- TXMD $1.17
- Analyst Decision
- FEBO
- TXMD
- Analyst Count
- FEBO 0
- TXMD 0
- Target Price
- FEBO N/A
- TXMD N/A
- AVG Volume (30 Days)
- FEBO 19.3K
- TXMD 35.2K
- Earning Date
- FEBO 07-22-2025
- TXMD 08-11-2025
- Dividend Yield
- FEBO N/A
- TXMD N/A
- EPS Growth
- FEBO N/A
- TXMD N/A
- EPS
- FEBO N/A
- TXMD N/A
- Revenue
- FEBO $17,110,653.00
- TXMD $1,841,000.00
- Revenue This Year
- FEBO N/A
- TXMD $427.09
- Revenue Next Year
- FEBO N/A
- TXMD N/A
- P/E Ratio
- FEBO N/A
- TXMD N/A
- Revenue Growth
- FEBO 11.58
- TXMD 53.55
- 52 Week Low
- FEBO $0.82
- TXMD $0.70
- 52 Week High
- FEBO $15.48
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- FEBO 45.49
- TXMD 47.76
- Support Level
- FEBO $0.82
- TXMD $1.13
- Resistance Level
- FEBO $1.26
- TXMD $1.24
- Average True Range (ATR)
- FEBO 0.10
- TXMD 0.09
- MACD
- FEBO -0.01
- TXMD 0.01
- Stochastic Oscillator
- FEBO 37.44
- TXMD 73.12
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.